Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Zhenbin Wei
Clinical application of base editing for treating β-thalassaemia
Abstract β-Thalassaemia is caused by reduced or absent production of β-haemoglobin1,2,3,4. Previously, we performed laboratory-scale electroporation of CD34+ haematopoietic stem and progenitor cells from patients with β-thalassaemia using a transformer base editor5,6. The aim was to target the binding motif of the transcription repressor BCL11A in the HBG1 and HBG2 promoters7 to reactivate fetal haemoglobin (HbF) production.
A multi-center clinical trial of allogeneic hematopoietic stem cell transplantation in transfusion-dependent thalassemia - Nature Communications
|
Abstract Allogeneic stem cell transplantation (allo-HSCT) has recently been approved as standard therapy for transfusion-dependent thalassemia (TDT) but remains limited to the use of HLA-matched sibling donors (MSDs), due to a lack of large-scale prospective studies evaluating the use of grafts from alternative donors. Here, we report the results of a non-randomised, interventional, phase 4 clinical trial evaluating allo-HSCT from alternative donors for the treatment of TDT.
By Rongrong Liu, Hongwen Xiao, Chunjie Qin, Jiong Hu, Jianming Luo, Hong Chang Chen, Xi Zhang, Xiaolin Yin, Guanye Nai, Guyun Wang, Zan Li, Wei Tang, Hua Zhang, Xiaotao Wang, Mei Lan, Chuande Liao, Tonghua Yang, Sanbin Wang, Jinxiong Huang, Yunyan He, Li Wang, Zhongming Zhang, Lianjin Liu, Zhenbin Wei, Lingling Shi, Meiqing Wu, Qi Zhou, Borje S. Andersson, Xiaojun Huang, Yongrong Lai
|
Nature
Verified
Basiliximab in the Prophylaxis of aGVHD for Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Thalassemia Major: A Prospective, Multicenter, Open‐Label, Randomized Controlled Study
To the Editor, We present the first prospective, multicenter, randomized controlled trial (RCT) evaluating Basiliximab prophylaxis for acute graft-versus-host disease (GVHD) in thalassemia major (TM) patients undergoing Matched unrelated donor hematopoietic stem-cell transplantation (MUD-HSCT). This study was registered at ClinicalTrials.gov [#NCT02342145]. This study addresses a critical unmet need in optimizing GVHD prevention strategies in this high-risk population.
Basiliximab in the Prophylaxis of aGVHD for Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Thalassemia Major: A Prospective, Multicenter, Open‐Label, Randomized Controlled Study
To the Editor, We present the first prospective, multicenter, randomized controlled trial (RCT) evaluating Basiliximab prophylaxis for acute graft-versus-host disease (GVHD) in thalassemia major (TM) patients undergoing Matched unrelated donor hematopoietic stem-cell transplantation (MUD-HSCT). This study was registered at ClinicalTrials.gov [#NCT02342145]. This study addresses a critical unmet need in optimizing GVHD prevention strategies in this high-risk population.
Sirolimus Plus Low‐Exposure Calcineurin Inhibitors as an Alternative Graft‐Versus‐Host Disease Prophylaxis in Calcineurin Inhibitor‐Intolerant Recipients: A Retrospective Study
Data Availability Statement The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Zhenbin
Contact Zhenbin, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack